Literature DB >> 9316829

Mechanism of down-regulation of alpha-2 adrenergic receptor subtypes.

D A Heck1, D B Bylund.   

Abstract

Long-term exposure to agonist down-regulates receptor expression for many G protein-coupled receptors. This decrease in receptor density could occur through either an increase in receptor degradation or a decrease in receptor synthesis. We studied the mechanism of down-regulation of the alpha-2A and alpha-2B adrenergic receptor subtypes transfected into the Chinese hamster ovary cell line as well as the alpha-2A receptor endogenous to the HT29 cell line. The rate constants for receptor appearance and disappearance were calculated from the recovery of receptor expression after irreversible inactivation of the existing receptor population with an alkylating agent. In the presence of the agonist norepinephrine, the receptor subtypes in all three cell lines down-regulated to about 50% with a half-time of 2.5 hr. When recovering in the presence of norepinephrine after irreversible inactivation, the rate of receptor degradation increased approximately 2-fold for all three cell lines with little change in the rate of synthesis. During this recovery, the transfected alpha-2A receptor exhibited a half-life of 3.0 hr, which agrees with the 2.7-hr half-time of down-regulation in the presence of norepinephrine. In contrast, the transfected alpha-2B receptor and the endogenous alpha-2A receptor had a half-life of 1.2 hr and 8.9 hr, respectively. For only the endogenous alpha-2A receptor, pertussis toxin increased the half-time of down-regulation to 9.8 hr, similar to the 8.9-hr receptor half-life in the presence of norepinephrine during recovery after irreversible inactivation. Our results indicate that the mechanism of down-regulation of the alpha-2A and -2B adrenergic receptor subtypes is an increase in the rate of receptor degradation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316829

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Homologous regulation of the alpha2C-adrenoceptor subtype in human hepatocarcinoma, HepG2.

Authors:  C Cayla; S Schaak; C Roquelaine; C Gales; F Quinchon; H Paris
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 2.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Desensitization of alpha 2A-adrenoceptor signalling by modest levels of adrenaline is facilitated by beta 2-adrenoceptor-dependent GRK3 up-regulation.

Authors:  Tasneem Bawa; Ghazi F Altememi; Douglas C Eikenburg; Kelly M Standifer
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

4.  Cannabinoid modulation of limbic forebrain noradrenergic circuitry.

Authors:  Ana F Carvalho; Kenneth Mackie; Elisabeth J Van Bockstaele
Journal:  Eur J Neurosci       Date:  2010-01-13       Impact factor: 3.386

5.  Gene expression profiles and signaling mechanisms in α2B-adrenoceptor-evoked proliferation of vascular smooth muscle cells.

Authors:  Anna Huhtinen; Vesa Hongisto; Asta Laiho; Eliisa Löyttyniemi; Dirk Pijnenburg; Mika Scheinin
Journal:  BMC Syst Biol       Date:  2017-06-28

6.  Role of Norepinephrine in IL-1β-Induced Chondrocyte Dedifferentiation under Physioxia.

Authors:  Saskia Speichert; Natalie Molotkov; Karima El Bagdadi; Andrea Meurer; Frank Zaucke; Zsuzsa Jenei-Lanzl
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

7.  Photopic light-mediated down-regulation of local α1A-adrenergic signaling protects blood-retina barrier in experimental autoimmune uveoretinitis.

Authors:  Andrea Stofkova; Daisuke Kamimura; Takuto Ohki; Mitsutoshi Ota; Yasunobu Arima; Masaaki Murakami
Journal:  Sci Rep       Date:  2019-02-20       Impact factor: 4.379

8.  The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment.

Authors:  Tasneem Bawa-Khalfe; Ghazi F Altememi; Chitra D Mandyam; Lindsay A Schwarz; Douglas C Eikenburg; Kelly M Standifer
Journal:  BMC Pharmacol       Date:  2007-12-20

9.  The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists.

Authors:  Huayun Deng; Ye Fang
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.